Characteristics and Clinical Outcomes of Patients With Hidradenitis Suppurativa (HS) Treated With Bimekizumab: A Canadian Retrospective Chart Review
Rattachement africain : ca. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
ABSTRACT Background Hidradenitis suppurativa (HS) is a chronic, recurrent inflammatory skin disease characterised by painful nodules, abscesses, and draining and non‐draining tunnels. Currently, there are two biologics approved in Canada for the treatment of moderate‐to‐severe HS, adalimumab (anti‐TNF) and secukinumab (anti‐IL‐17A). However, there remains a high unmet need to manage moderate‐to‐severe HS. Bimekizumab (BKZ), a humanised IgG monoclonal antibody that inhibits IL‐17A and IL‐17F, offers broader IL‐17 pathway inhibition and may provide enhanced clinical benefit relative to IL‐17A‐selective inhibitors. Objectives We aimed to evaluate disease characteristics and real‐world clinical outcomes in Canadian patients with moderate‐to‐severe HS treated with BKZ. Methods This retrospective chart review included 27 patients with moderate‐to‐severe HS prior to initiation of BKZ. All patients were initiated on BKZ 320 mg every 4 weeks (Q4W) for 16 weeks followed by every 8 weeks (Q8W) (except for two patients on every 2 weeks [Q2W]) thereafter. Results Twenty‐two patients (81%) had severe disease with majority having an abscess and nodule (AN) count > 5, draining tunnels, pain scores ≥ 6, mean DLQI of 23, and significant comorbidities; 18 patients (67%) had Hurley stage III disease. Patients in this cohort had received multiple prior treatments including oral antibiotics ( n = 26, 96%), adjunct systemics ( n = 25, 93%) and intravenous ertapenem ( n = 3, 11%). Prior to receiving BKZ, 25 patients (93%) were treated with adalimumab and 8 (30%) with secukinumab. BKZ was generally well‐tolerated, with no treatment‐related adverse events reported in 16 patients (59%). Candidiasis was the most common adverse event ( n = 6, 22%) and did not lead to discontinuation. Median AN count, draining tunnels, pain scores, and disease severity decreased at first follow‐up and continued to improve thereafter. No new safety signals emerged. Conclusions These findings support BKZ as a promising therapeutic option for moderate‐to‐severe HS and highlight the continued need for effective treatments in this population.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Characteristics and Clinical Outcomes of Patients With Hidradenitis Suppurativa (HS) Treated With Bimekizumab: A Canadian Retrospective Chart Review
- Date Crossref
- 10/01/2026
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Dalhousie University Division of Clinical Dermatology & pays non établi dans la noticeUniversité ou école supérieure
-
Probity Medical Research pays non établi dans la noticeStructure de recherche
-
Memorial University of Newfoundland Dermatology pays non établi dans la noticeUniversité ou école supérieure
-
St. John’s Health Sciences Centre pays non établi dans la noticeÉtablissement de santé
-
Newfoundland and Labrador Centre for Applied Health Research pays non établi dans la noticeStructure de recherche
-
La Cité Médicale pays non établi dans la noticeÉtablissement de santé
-
Université Laval Dermatology Division pays non établi dans la noticeUniversité ou école supérieure
-
University Health Network Division of Dermatology pays non établi dans la noticeÉtablissement de santé
-
Saskatoon City Hospital pays non établi dans la noticeÉtablissement de santé
-
University of Saskatchewan Dermatology Division pays non établi dans la noticeUniversité ou école supérieure
-
Saskatoon Medical Imaging pays non établi dans la noticeÉtablissement de santé
-
Brunswick Dermatology Center Fredericton New Brunswick Canada pays non établi dans la noticeInstitution
Division of Clinical Dermatology & — Dalhousie University, Probity Medical Research et Dermatology — Memorial University of Newfoundland, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.